CNTX-6016 / Centrexion Therap - LARVOL DELTA

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Centrexion Therapeutics | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | Trial completion date: Mar 2022 ➔ Aug 2023 | Trial primary completion date: Dec 2021 ➔ Aug 2023

Phase classification • Trial completion • Trial completion date • Trial primary completion date • Diabetic Neuropathy • Pain

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN (clinicaltrials.gov) - P1/2; N=50; Recruiting; Sponsor: Centrexion Therapeutics

Clinical • New P1/2 trial • Diabetic Neuropathy • Pain

Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors (GlobeNewswire) - "Centrexion Therapeutics Corporation...today announced that it has raised $40.5 million of cash....Inclusive of this $40.5 million raise, Centrexion has in excess of $75 million of cash to deploy for the continued in-licensing of drug candidates and development of its portfolio of four clinical-stage drug candidates including: 4975 (TRPV1 agonist) in Phase 3 for knee osteoarthritis pain; 6970 (CCR2 antagonist) in Phase 2a for osteoarthritis pain; 6016 (CB2 agonist) in Phase 1b/2a for diabetic neuropath; 0290 (SSTR4 agonist) in Phase 2a for neuropathic, musculoskeletal and inflammatory pain."

Financing • CNS Disorders • Musculoskeletal Pain • Neuralgia • Osteoarthritis • Pain • Peripheral Neuropathic Pain

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects (clinicaltrials.gov) - P1; N=68; Completed; Sponsor: Centrexion Therapeutics

Clinical • New P1 trial

CORRECTION - Centrexion Therapeutics (GlobeNewswire, Centrexion Therapeutics) - "BOSTON, Sept 04, 2019 (GLOBE NEWSWIRE) -- In a release issued earlier today by Centrexion Therapeutics Corporation (NASDAQ: CNTX), please note that the headline should read "Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference," as opposed to "Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations at PAINWeek 2019 National Conference." The corrected release follows:. Centrexion Therapeutics Announces CNTX-4975, CNTX-6970 and CNTX-6016 Data Presentations at PAINWeek 2019 National Conference."

Clinical data